tbuckley/cabot-search huggingface dataset:
AB0655 Ultrasound b-lines in the evaluation of interstitial lung disease in patients with systemic sclerosis: cut-off point definition for the presence of pulmonary fibrosis
Authors: M Tardella, M Di Carlo, M Carotti, E Filippucci, W Grassi, F Salaffi
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Although in Systemic Sclerosis (SSc) the cutaneous manifestations are the most noticeable features, lung involvement guides the disease prognosis. High resolution computed tomography (HRCT) is the mainstay for the detection of the interstitial lung disease (ILD). However, exposure to ionising radiation is a major limitation for the repetition of this examination. Over the last years, lung ultrasound (US) gained an intriguing potential in the evaluation of several pulmonary condition, and in previous studies was found a significant correlation between US score and HRCT score [1]. <h3>Objectives</h3> To establish the cut-off point of the US B-lines number for detecting the presence of SSc-ILD. <h3>Methods</h3> Patients with SSc-ILD underwent chest HRCT, lung US, pulmonary function test, and clinical assessment. Exclusion criteria were represented by the presence of a coexisting congestive heart failure and other lung or pleural diseases (i.e., pneumonia, pleural effusion). HRCT were scored for the presence of ILD by an experienced radiologist, in accordance with the Warrick method. US assessment was performed by a US skilled rheumatologist, blinded to the HRCT results, and included the bilateral evaluation of 14 lung intercostal spaces (LIS) [2]. In each LIS the number of B-lines was recorded and summed. To test discriminant validity we used the receiver operating characteristic (ROC) curve analysis applying a Warrick score of 7 as external criterion for the presence of SSc-ILD. <h3>Results</h3> Forty patients completed the study. The US B-lines number and the Warrick score confirmed an excellent correlation (Spearman9s rho: 0.819, p&lt;0.001). The ROC curve analysis revealed that the presence of 10 US B-lines is the cut-off point with the greatest positive likelihood ratio (12.52) for the presence of SSc-ILD (Table). <h3>Conclusions</h3> The detection of 10 B-lines is highly predictive for the HRCT presence of SSc-ILD. In SSc patients, a lung US follow-up can optimize the employment of chest HRCT. <h3>Disclosure of Interest</h3> None declared
AB0670 Clinical and laboratory manifestations of rnp-positive patients with systemic sclerosis
Authors: LP Ananyeva, RU Shayakhmetova, OA Koneva, MN Starovoitova, OV Desinova, OB Ovsyannikova
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Among patients, who meet the classification criteria for systemic sclerosis (SSc), there are the patients without specific SSc anti-nuclear antibodies and who are positive for antibodies to ribonucleoprotein (RNP). The clinical significance of the RNP antibodies in SSc is not clear. <h3>Objectives</h3> To investigate clinical and laboratory characteristics of SSc patients positive for antibodies to RNP. <h3>Methods</h3> The study included 52 patients (49 women and 3 men, mean age 44.2±15 years, median disease duration from the beginning of Raynaud9s phenomenon 11.2±7years) who met the classification criteria of SSc (ACR/EULAR 2013) and have high level (&gt;200 U/ml) of antibodies to RNP-70 (determined by ELISA, range 0–25 U/ml). Clinical, laboratory, and immunologic data were collected on all patients. <h3>Results</h3> All the patients met the criteria for classification of SSc ACR/EULAR 2013 (table 1). Other prevalent clinical manifestations were gastroesophageal reflux in 63, 5% of patients, joints involvement in 58%, myositis in 30, 7%, serositis in 27.5% (including 23% of pericarditis). All patients were positive for antinuclear factor (Hep-2) and in some cases RF, anti-SS-A, anti-SS-B, anti-Sm and anti-dsDNA antibodies were identified. The increased levels of CRP and/or ESR were found in 56% of cases. Among the SSc patients, there were 38 (73%) who satisfied for the classification criteria for mixed connective tissue disease (MCTD) proposed by Kasukawa et al. (1987). <h3>Conclusions</h3> In the group under study the limited form of SSc dominated, with high frequency of the different manifestations of vasculopathy, esophagus, joint and muscle disorders symptoms. A subtype of RNP-positive SSc patients often met the criteria for MCTD. This fact makes it reasonable to discuss the possibility of overlap-syndrome between these two diseases. <h3>Disclosure of Interest</h3> None declared
SAT0300 High proportions of dementia among sle patients: a big data analysis
Authors: O Gendelman, S Tiosano, D Comaneshter, A Cohen, Y Shoenfeld, H Amital
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting wide range of systems including the peripheral and central nervous system<sup>1</sup>. Cognitive impairment leading to dementia is one of the harmful central nervous system manifestations of SLE<sup>2</sup>. <h3>Objectives</h3> The aim of this study was to investigate the association of SLE and dementia. <h3>Methods</h3> A cross-sectional study was performed utilizing Clalit Health Care database, the largest HMO in Israel with more than 4.4 million enrollees. SLE patients were compared in a 1:5 ratio to age and sex matched controls. Chi-square and <i>t</i> tests were used for univariate analysis, and a logistic regression model was used for multivariate analysis. <h3>Results</h3> The study included 4886 SLE patients and 24,430 age and sex frequency matched controls without SLE. The proportion of dementia was higher among SLE patients compared to controls (1.56% and 0.51% respectively; p&lt;0.001). This finding was consistent across all age groups by univariate analysis. In a multivariate logistic regression analysis, SLE was significantly associated with dementia (OR =2.039, 95% CI =1.110–2.039). <h3>Conclusions</h3> SLE is significantly associated with dementia. This finding should give rise to search for SLE in patients with an ambiguous cause for dementia, especially those with an early onset cognitive decline. <h3>References</h3> Tsokos GC. Systemic Lupus Erythematosus. N Engl J Med. 2011;365(22):2110–2121. Liang MH, Corzillius M, Bae SC, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599–608. <h3>Disclosure of Interest</h3> None declared
SAT0210 Improvement of disease activity in a 5-year cohort of rheumatoid arthritis patients treated under treat to target recommendations receiving biological therapy
Authors: P Santos-Moreno, D Gomez, E Castillo, R Giraldo, G Ballesteros, L Villarreal, J Bello, D Buitrago-Garcia
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Treat to Target (T2T) strategy becomes from the need to develop therapeutic targets and tools to achieve defined outcomes in rheumatoid arthritis (RA), this strategy has become recognized as a standard of good practice embodying the principle that rapid attainment of remission, or low disease activity, can halt joint damage and maintain good quality of life. However, there is no direct comparison between biologics in cohorts of patients with long-standing RA using T2T approach in real-life settings, which could have implications in treatment decisions and health economics. <h3>Objectives</h3> The aim of this study was to describe global change in Disease Activity Score 28 (DAS28) using T2T strategy for a 5 year period in patients with biological therapy in a large cohort of patients from a Colombian specialized in RA center with multidisciplinary approach. <h3>Methods</h3> A descriptive dynamic cohort study was performed. Records of patients using biological DMARD treatment (Anti-TNF and others) from specialized in RA center were reviewed; those patients were followed-up under T2T standards. Clinical follow-up was according to DAS28 as follows: every 3–5 weeks (DAS28 &gt;5.1), every 7–9 weeks (DAS28 ≥3.1 and ≤5.1), and every 11–13 weeks (DAS28 &lt;3.1). Therapy had to be adjusted with DAS28 &gt;3.2 unless patient9s conditions don9t permit it. We divided patients in three groups: low disease activity (LDA), moderate disease activity (MDA) and severe disease activity (SDA) patients. Descriptive epidemiology was done, percentages and averages were calculated; the median of each variable was analyzed using t-Student assuming normality for DAS28 distribution and the level activity disease was analyzed using Pearson9s statistics. <h3>Results</h3> During 60 month period we included 695 patients with biological therapy, 85% were female and 15% male. Mean age was 58 years ± 11. At beginning mean DAS28 was 4.1±1.1 and 20% of patients were in SDA, and 55% in MDA. At the end of 5 year period mean DAS was 3.2±0.89 and only 7% of patients were in SDA and 33% in MDA. The median was analyzed using t-Student assuming normality for DAS28 distribution. It showed statistical significant improvement (p&lt;0.00). <h3>Conclusions</h3> There was a global improvement of DAS28 in a cohort of RA patients receiving biological therapy followed and treated under recommendations of T2T approach demonstrating that with the strategies mentioned above it is possible to obtain a good control of the activity of the disease. <h3>Disclosure of Interest</h3> None declared
THU0710 Validation of new weighted scoring system to predict modified health assessment questionnaire scores in patients with rheumatoid arthritis using national database of rheumatic diseases in japan during 2009 and 2014
Authors: K Ono, S Ohashi, Y Kadono, H Oka, J Hirose, T Matsumoto, N Izawa, M Naito, J Nishino, S Tanaka, S Tohma
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> We reported the impact of joint diseases on modified health assessment questionnaire (MHAQ) scores determined using 2011 data from NinJa (National Database of Rheumatic Diseases by iR-net in Japan). The MHAQ score was significantly associated with disease in almost all joints and physical ability tended to become aggravated. We also developed a joint-weighted scoring system from odds ratios. Respective integer scores assigned to disease in bilateral and unilateral joints comprised shoulder, 4 and 2; elbow, 3 and 2; wrist, 2 and 2; hip, 0 and 3; knee, 3 and 2; ankle, 2 and 2; finger, 1 and 1. Statistical analyses indicated a cut-off at 3 points using this system (Ono K, et al., Modern Rheumatology, 2016). <h3>Objectives</h3> To validate the weighted scoring system using NinJa data from 2009 and 2014. <h3>Methods</h3> We analyzed data from 7,189 and 13,459 patients listed in the NinJa database during 2009 and 2014. The presence or absence of disease in each joint (swelling and/or tenderness were considered to indicate active disease) and whether the disease was bilateral or unilateral were investigated. We calculated joint scores for each patient using a weighted scoring system and then created ROC curves for each patient based on total scores. <h3>Results</h3> Patients in the 2009 and 2014 groups were aged 62.4±12.6 and 64.1±12.8 years, median DAS28 CRP values were 2.9 and 2.4, and total joint scores were 3.4 and 2.4 with a significant difference (p&lt;0.05; Wilcoxon signed-rank test) between the two groups. Analyses of ROC curves generated from scores derived using the new system and MHAQ revealed a cut-off of 3 points (same as 2011); AUC, 0.72, 0.68 (Table 1). <h3>Conclusions</h3> Disease activity changed from moderate to low in the NinJa cohorts and the scoring system was validated for the years 2009 and 2014. The weighted scoring system appears useful to predict functional disability in a simpler way by examining each joint rather than changes in disease activity among patients with RA. <h3>References</h3> Ono K, et al., The impact of joint disease on the Modified Health Assessment Questionnaire scores in rheumatoid arthritis patients: A cross-sectional study the National Database of Rheumatic Diseases by iR-Net in Japan. Modern Rheumatology, 2016(4): 529–533. <h3>Disclosure of Interest</h3> None declared
FRI0051 Early arthritis induces disturbances at bone nanostructural level reflected in decreased tissue hardness
Authors: B Vidal, R Cascão, M Finnilä, I Lopes, S Saarakkala, P Zioupos, H Canhão, J Fonseca
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Arthritis induces joint erosions and skeletal bone fragility. <h3>Objectives</h3> The main goal of this work was to analyze the early arthritis induced events at bone tissue level. <h3>Methods</h3> Eighty-eight Wistar rats were randomly housed in experimental groups, as follows: adjuvant induced arthritis (N=47) and a control healthy group (N=41). Rats were monitored during 22 days for the inflammatory score, ankle perimeter and body weight and sacrificed at different time points (11 and 22 days post disease induction). Bone samples were collected for histology, micro-CT, 3-point bending, nanoindentation and Fourier transformed infrared spectroscopy (FTIR) analysis. Blood samples were also collected for bone turnover markers and systemic cytokine quantification. <h3>Results</h3> At bone tissue level, measured by FTIR analysis and nanoindentation, there was a reduction of the mineral and collagen content and of hardness in the arthritic group, associated with an increase of the ratio of bone concentric to parallel lamellae and of the area of the osteocyte lacuna. In addition, increased bone turnover and changes in the microstructure and mechanical properties were observed in arthritic animals, since the early phase of arthritis, when compared with healthy controls. <h3>Conclusions</h3> Arthritis induces very early changes at bone tissue level characterized by decreased tissue hardness and of collagen and mineral content. These observations highlight the pertinence of immediate control of inflammation in the initial stages of arthritis. <h3>Disclosure of Interest</h3> None declared
Haploidentical Natural Killer Cell Infusion Induces Remission in Non-Hodgkin Lymphoma and Overcomes Resistance to Rituximab
Authors: Veronika Bachanova, Dhifaf Sarhan, Todd E. DeFor, Sarah Cooley, Angela Panoskaltsis-Mortari, Michael R. Verneris, Bruce R. Blazar, Julie Curtsinger, Linda J. Burns, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood (2016)
SAT0360 Myositis-specific and myositis-associated autoantibodies in patient with dermatomyositis / polymyositis; comparison between line blot and enzyme-immunoassay assays
Authors: S Nakashima, T Kameda, M Izumikawa, H Shimada, H Ozaki, R Wakiya, A Kondou, N Kadowaki, H Dobashi
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> MESACUP<sup>TM</sup> test (enzyme-immunoassay assays; TIF1γ, MDA5, Jo-1, EJ, PL-7, PL-12, and KS; MBL) (MESA) is used for a diagnosis of idiopathic inflammatory myopathies (IIMs) in Japan. On the other hand, EUROLINE myositis Profile 3 (line blot; EUROIMMUN) (EURO) can analyze plural Myositis-specific autoantibodies (MSA: Mi-2, Jo-1, SRP, PL-7, PL-12, EJ, OJ) and Myositis-associated autoantibodies (MAA; Ku, PM-Scl) at the same time, which is used commercially in Western countries. However, the difference between utility of MESA and that of EURO haven9t be disclosed. <h3>Objectives</h3> To clarify difference between utility of EURO and MESA, and extract the problem of respective examination. <h3>Methods</h3> We enrolled 58 patients diagnosed DM/PM in our facility. Polymyositis (PM) and dermatomyositis (DM) were diagnosed according to Bohan and Peter9s criteria.<sup>1)</sup> The MAA and MSA were analyzed using MESA and EURO. In case of MESA (+), MSA (anti-Jo1, anti-PL7, anti-PL12, anti-KS) were identified by specific ELISA. When those results were different, we analyzed by immunoprecipitation. And we analyzed the association between each autoantibody and clinical features. <h3>Results</h3> MSA and MAA were detected in 43/58 (74%) (anti-PL7: 12, anti-Jo1: 7, anti-EJ: 3, anti-PL12: 1, anti-OJ: 0, anti-Ro52: 27, anti-PM-Scl75: 7, anti-Ku: 6, anti-PM-Scl100: 1) by EURO. On the other hand, MSA and MAA were detected in 30/58 (52%) (anti-PL7: 9, anti-Jo1: 7, anti-EJ: 4, TIF1γ: 4, MDA5: 3, U1RNP: 3) by MESA. Five patients were MESA (-) and EURO (-). In the case of ARS positive patient, Two of EURO (-) patients was positive in MESA, respectively Jo1 and EJ. Three of MESA (-) patients was positive in EURO. Although MESA(-) and EURO(+) patients had plural MSA and MAA (PL7+Jo1, PL7+PL12, PL7+Ku), MSA and MAA weren9t detected by immunoprecipitation in MESA(-) and EURO(+) patients. Two of patients that detected plural MSA or MAA had rapid progressive ILD. (Association between clinical manifestations and MSA, MAA) All patients with anti-ARS (anti-Jo-1, anti-PL-7, anti-PL-12 and anti-EJ) had ILD. In addition, anti-ARS were associated with arthritis and mechanic9s hands. Anti-Mi-2 positive patients didn9t have ILD. Patients detected anti-PM-Scl75, anti-PM-Scl100, anti-Ku were almost overlap syndrome. All of Anti-SRP positive patients was PM. <h3>Conclusions</h3> EURO is a convenient and reliable method useful for detection of MSA and MAA. It was suggested the patients whom plural antibodies were detected by EURO have unique clinical course in others. <h3>References</h3> Bohan, A., Peter, J.B., 1975. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403–407. <h3>Disclosure of Interest</h3> None declared
Disturbed Placental Imprinting in Preeclampsia Leads to Altered Expression of DLX5, a Human-Specific Early Trophoblast Marker
Authors: Julianna Zadora, Manvendra Singh, Florian Herse, Lukasz Przybyl, Nadine Haase, Michaela Golic, Hong Wa Yung, Berthold Huppertz, Judith E. Cartwright, Guy Whitley, Guro M. Johnsen, Giovanni Levi, Annette Isbruch, Herbert Schulz, Friedrich C. Luft, Dominik N. Müller, Anne Cathrine Staff, Laurence D. Hurst, Ralf Dechend, Zsuzsanna Izsvák
Journal: Circulation (2017)

Preeclampsia is a complex and common human-specific pregnancy syndrome associated with placental pathology. The human specificity provides both intellectual and methodological challenges, lacking a robust model system. Given the role of imprinted genes in human placentation and the vulnerability of imprinted genes to loss of imprinting changes, there has been extensive speculation, but no robust evidence, that imprinted genes are involved in preeclampsia. Our study aims to investigate whether disturbed imprinting contributes to preeclampsia.We first aimed to confirm that preeclampsia is a disease of the placenta by generating and analyzing genome-wide molecular data on well-characterized patient material. We performed high-throughput transcriptome analyses of multiple placenta samples from healthy controls and patients with preeclampsia. Next, we identified differentially expressed genes in preeclamptic placentas and intersected them with the list of human imprinted genes. We used bioinformatics/statistical analyses to confirm association between imprinting and preeclampsia and to predict biological processes affected in preeclampsia. Validation included epigenetic and cellular assays. In terms of human specificity, we established an in vitro invasion-differentiation trophoblast model. Our comparative phylogenetic analysis involved single-cell transcriptome data of human, macaque, and mouse preimplantation embryogenesis.We found disturbed placental imprinting in preeclampsia and revealed potential candidates, including GATA3 and DLX5, with poorly explored imprinted status and no prior association with preeclampsia. As a result of loss of imprinting, DLX5 was upregulated in 69% of preeclamptic placentas. Levels of DLX5 correlated with classic preeclampsia markers. DLX5 is expressed in human but not in murine trophoblast. The DLX5high phenotype resulted in reduced proliferation, increased metabolism, and endoplasmic reticulum stress-response activation in trophoblasts in vitro. The transcriptional profile of such cells mimics the transcriptome of preeclamptic placentas. Pan-mammalian comparative analysis identified DLX5 as part of the human-specific regulatory network of trophoblast differentiation.Our analysis provides evidence of a true association among disturbed imprinting, gene expression, and preeclampsia. As a result of disturbed imprinting, the upregulated DLX5 affects trophoblast proliferation. Our in vitro model might fill a vital niche in preeclampsia research. Human-specific regulatory circuitry of DLX5 might help explain certain aspects of preeclampsia.
Profiling movement and gait quality using accelerometry in children’s physical activity: consider quality, not just quantity
Authors: Cain Craig Truman Clark
Journal: British Journal of Sports Medicine (2017)

The overarching aim of this PhD was to characterise and profile children’s physical activity movement quality. Further, chapter specific aims were, (1) to verify the validity and reliability of accelerometry in a mechanical and laboratory setting, (2) to characterise and profile movement quality according to body mass index (BMI) and (3) to characterise and profile movement quality during recess and free play.

Regular physical activity during childhood is positively associated with a variety of physical, social and psychological factors.1–3 While there are a plethora of methods and techniques to quantify overall activity or energy expenditure, there is a paucity of research demonstrating objective methods to empirically derive quality of movement and its relationship with health, performance and risk factors.4 

1.  Reliability and validity …
FRI0348 Associated inflammatory syndromes in takayasu's arteritis: many faces of a disease
Authors: SN Esatoglu, AM Celik, D Ucar, AF Celik, S Ugurlu, G Hatemi, M Melikoglu, I Fresko, V Hamuryudan, H Ozdogan, S Yurdakul, H Yazici, E Seyahi
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Case reports and series suggest that Takayasu9s arteritis (TA) can co-exist with various inflammatory disorders. <h3>Objectives</h3> We conducted a formal study to look specifically at the frequency of inflammatory disorders and symptoms in a large cohort of TA followed by a single tertiary center. <h3>Methods</h3> There were 238 patients registered with a diagnosis of TA. Of these, 19 died, 18 were lost to follow-up and 3 did not wish to response our questionnaire. The remaining 198 patients were called back at the outpatient clinic. A standardized form sought whether the patient was also diagnosed as inflammatory bowel disease (IBD), ankylosing spondylitis (AS), Behçet9s syndrome (BS), amyloidosis, uveitis, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (pSS), Sjögren syndrome, psoriatic arthritis, inflammatory myositis, small vessel vasculitis, autoimmune/demyelinating or any other inflammatory disorder. <h3>Results</h3> Overall, 198 (175 F/ 23 M) patients were studied. The mean age at the time of TA diagnosis was 34±12 years. Subclavian artery was the most common involved artery (84%), followed by common carotids (78%) and aorta (65%). Currently, while 25 (16%) patients were off treatment, 72 (47%) patients were using glucocorticoids, 47 (31%) azathioprine, 32 (21%) methotrexate and 44 (29%) biological agents. We identified in total 37 (19%) patients with inflammatory diseases (IBD: n=12; AS: n=15; and BS: n=10). Table shows their demographic characteristics. Among the remaining 161 patients, the most frequent feature was inflammatory back pain (36%), followed by recurrent oral ulcers (15%), erythema nodosum (11%), arthritis (10%), papulopustular lesions (7%), uveitis (4%), and genital ulcer (1%). It was noted that inflammatory back was mostly located on the dorsal area. Regarding autoimmune diseases, we also observed RA (n=3), psoriasis (n=2), autoimmune hepatitis (n=2), SS (n=1) and SSc (n=1). <h3>Conclusions</h3> TA does co-occur with IBD, AS or BS in about 1/5 of the patients, at least in a hospital setting and without a clear temporal pattern. This could be due to the close association of TA with MHC class-1 diseases. In addition, the high prevalence of inflammatory back pain in the dorsal spine in TA needs further scrutiny. <h3>Disclosure of Interest</h3> None declared